A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
2상
완료
NCT04917861
| 대상 질환 | Zika Virus |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | ModernaTX, Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 808 명 |
|---|
| 중재(약물) | mRNA-1893 |
|---|
| 시작일 | 2021년 6월 7일 |
|---|
| 완료일 | 2024년 7월 26일 |
|---|
| 결과 공개일 | 2025년 9월 25일 |
|---|
요약
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Up to 7 days post-vaccination · Participants
| Placebo | 86 Participants |
|---|
| mRNA-1893 Low Dose (2-Dose Regimen) | 164 Participants |
|---|
| mRNA-1893 High Dose (2-Dose Regimen) | 183 Participants |
|---|
| mRNA-1893 High Dose (1-Dose Regimen) | 163 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs)
Up to 28 days post-vaccination · Participants
| Placebo | 39 Participants |
|---|
| mRNA-1893 Low Dose (2-Dose Regimen) | 47 Participants |
|---|
| mRNA-1893 High Dose (2-Dose Regimen) | 52 Participants |
|---|
| mRNA-1893 High Dose (1-Dose Regimen) | 45 Participants |
|---|
Number of Participants With Serious Adverse Events (SAEs), AEs of Special Interest (AESIs)
Day 1 through Day 196 for Main Study and Day 197 through Day 700 for Extension Period · Participants
| Main Study: Placebo | 5 Participants |
|---|
| Main Study: mRNA-1893 Low Dose (2-Dose Regimen) | 2 Participants |
|---|
| Main Study: mRNA-1893 High Dose (2-Dose Regimen) | 4 Participants |
|---|
| Main Study: mRNA-1893 High Dose (1-Dose Regimen) | 7 Participants |
|---|
| Extension Period: Placebo | 5 Participants |
|---|
| Extension Period: mRNA-1893 Low Dose (2-Dose Regimen) | 4 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.